Abstract
The biological mechanism of gene silencing by messenger RNA (mRNA) inhibition has been harnessed to develop therapies to target specific proteins, such as those involved in lipid metabolism. The first of these, inclisiran, is available in Australia for reducing levels of LDL-cholesterol and is PBS listed for people with familial and nonfamilial hypercholesterolaemia.
| Original language | English |
|---|---|
| Pages (from-to) | 32-37 |
| Number of pages | 6 |
| Journal | Medicine Today |
| Volume | 25 |
| Issue number | 7 |
| Publication status | Published - Jul 2024 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Messenger RNA
- Lipids
- Inclisiran
Fingerprint
Dive into the research topics of 'From Nobel Prize to clinical practice: An update on messenger RNA-based therapies for lipid disorders'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver